Breaking: CHD Responds to News of Life-Threatening Reaction to Pfizer COVID Vaccine. Will Regulators Take Action?

In August, CHD asked regulators to investigate the use of polyethylene glycol (PEG) in COVID mRNA vaccines, which could have caused the severe allergic reactions reported this week by two of the first UK recipients of Pfizer’s vaccine.

Children’s Health Defense

Media outlets are reporting that two individuals who received the Pfizer-BioNTech COVID-19 mRNA vaccine developed severe anaphylactic reactions following the injection.

England’s National Health Service (NHS) warned Wednesday that people “with a history of a significant allergic reaction to a vaccine, medicine or food” should not be given the COVID-19 vaccine developed by U.S. pharmaceutical giant Pfizer and Germany’s BioNTech. UK’s Medical and Health products Regulatory Agency, as reported by The Wall Street Journal, reminded health-care workers that vaccinations should only be carried out in facilities where resuscitation measures are available.

These warnings came after two National Health Service employees who were part of the first tranche to receive the vaccine on Tuesday suffered adverse reactions.

NHS England said in a statement that both of the medical workers who experienced anaphylactoid reactions to the Pfizer vaccine had a “strong past history of allergic reactions.”

According to these news reports, documents published by the two companies showed that people with a history of severe allergic reactions were excluded from the clinical trials.  Therefore, this life-threatening adverse safety signal did not appear in their clinical trial safety data.

On Aug. 26, Children’s Health Defense (CHD) sent a letter to Dr. Jerry Menikoff, director office for Human Research Protections Dept. of Health and Human Services regarding the Phase III Moderna mRNA-1273 vaccine. The letter requested the Office for Human Research Protections investigate the use of polyethylene glycol (PEG) in Moderna’s COVID-19 mRNA vaccine. Pfizer’s COVID vaccine, which also uses mRNA technology, also contains PEG.

Approximately 8% of the U.S. population has highly elevated levels of anti-PEG antibodies. The concerns we laid out in our letter about the Moderna vaccine were related to the fact that injecting a PEG-containing vaccine into individuals with pre-existing PEG antibodies could lead to life-threatening anaphylaxis.

Such was the case with a member of CHD, Harold Gielow, a retired military Lt. Col USMC who suffers with severe anaphylactic response to polyethylene glycol. In fact, the last time Gielow was exposed to an injected drug that contained PEG, he went pulseless, requiring an injection of epinephrine. His PEG allergy was diagnosed by Johns Hopkins. (continue reading)



'Breaking: CHD Responds to News of Life-Threatening Reaction to Pfizer COVID Vaccine. Will Regulators Take Action?' has no comments

Be the first to comment this post!

Would you like to share your thoughts?

Your email address will not be published.

©Copyright One Radio Network 2019 • All rights reserved. | Site built by RedLotus Austin
The information on this website and talk shows is solely for informational and entertainment purposes. IT IS NOT INTENDED TO PROVIDE MEDICAL ADVICE. Neither the Editors, producers of One Radio Network, Patrick Timpone, their guests or web masters take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading or following the information contained on this website in written or audio form, live or podcasts. The publication of this information does not constitute the practice of medicine, and this information does not replace the advice of your physician or other health care provider. Before undertaking any course of treatment, the reader must seek the advice of their physician or other health care provider and take total responsibility for his or her actions at all times. Patrick Joseph of the family of Timpone, a man...All rights reserved, without recourse.